YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

A Study of Prescription Analysis on Patients with Ischemic Heart Disease and Evaluation of Antihypertensive Drug Use in General Hospital

종합병원 허혈성 심장질환 환자의 항고혈압약제 사용 현황 및 평가

  • Moon, Kyoung-Sil (Department of Pharmacology, College of Pharmacy, Chung-Ang University) ;
  • Song, Hyun-Ju (Department of Pharmacology, College of Pharmacy, Chung-Ang University) ;
  • Sohn, Uy-Dong (Department of Pharmacology, College of Pharmacy, Chung-Ang University)
  • 문경실 (중앙대학교 약학대학 약물학실) ;
  • 송현주 (중앙대학교 약학대학 약물학실) ;
  • 손의동 (중앙대학교 약학대학 약물학실)
  • Published : 2007.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Treatment of hypertension is important in reducing death and attack rates by Ischemic heart disease (IHD). The purposes of this study are to investigate recent prescriptions for patients with IHD and to evaluate antihypertensive drug use. On the basis of the guidelines proposed by Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, we analyzed prescriptions of antihypertensive drugs for patients with IHD. It is necessary to set up new guideline for appropriate treatment to lower death and attack rates for patients with IHD.

Keywords

References

  1. 보건복지부 : 심뇌혈관질환 종합대책 (보도 참고자료) (2006)
  2. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L. Jr., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T. Jr. and Roccella, E. J.: Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National heart, lung, and blood institute; national high blood pressure education program coordinating committee : Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42, 1206 (2003) https://doi.org/10.1161/01.HYP.0000107251.49515.c2
  3. Neal, B., MacMahon, S. and Chapman, N. : Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 356, 1955 (2000)
  4. Ogden, L. G., He, J., Lydick, E. and Whelton, P. K.: Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 35, 539 (2000)
  5. European Society of Hypertension-European Society of Cardiology Guidelines Committee : 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011 (2003) https://doi.org/10.1097/00004872-200306000-00001
  6. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group : Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42, 239 (2003) https://doi.org/10.1161/01.HYP.0000086521.95630.5A
  7. Verdecchia, P., Reboldi, G., Angeli, F., Gattobigio, R., Bentivoglio, M., Thijs, L., Staessen, J. A. and Porcellati, C. : Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46, 386 (2005) https://doi.org/10.1161/01.HYP.0000174591.42889.a2
  8. Svensson, R, de Faire, U., Sleight, P., Yusuf, S. and Ostergren, J. : Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 38, E28 (2001) https://doi.org/10.1161/01.HYP.38.1.1
  9. Franklin, S. S., Wachtell, K., Papademetriou, V, Olsen, M. H., Devereux, R. B., Fyhrquist, F., Ibsen, H., Kjeldsen, S. E. and Dahlof, B. : Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension 46, 492 (2005) https://doi.org/10.1161/01.HYP.0000179604.42845.8d
  10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blockers vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981 (2002)
  11. Leenen, F. H., Nwachuku, C. E., Black, H. R., Cushman, W. C., Davis, B. R., Simpson, L. M., Alderman, M. H., Atlas, S. A., Basile, J. N., Cuyjet, A. B., Dart, R., Felicetta, J. V., Grimm, R. H., Haywood, L. J., Jafri, S. Z., Proschan, M. A., Thadani, U., Whelton, P. K. and Wright, J. T. : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group : Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48, 374 (2006) https://doi.org/10.1161/01.HYP.0000231662.77359.de
  12. Gibbons, R. J., Abrams, J., Chatterjee, K., Daley, J., Deedwania, P. C., Douglas, J. S., Ferguson, T. B. Jr., Fihn, S. D., Fraker, T. D. Jr., Gardin, J. M., O'Rourke, R. A., Pasternak, R. C. and Williams, S. V. : ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J. Am. Coll. Cardiol. 41, 159 (2003)